

REGENERON PHARMACEUTICALS INC  
 Form 4  
 September 25, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Sanofi

2. Issuer Name and Ticker or Trading Symbol  
 REGENERON  
 PHARMACEUTICALS INC  
 [REGN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
 \_\_\_ Officer (give title below) \_\_\_ Other (specify below)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 09/23/2015

54, RUE LA BOETIE  
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

PARIS, IO 75008

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(A) or (D)	Price			
Common Stock	09/23/2015		P		2,600 <u>(1) (2)</u>	A	\$ 523.4327 <u>(1) (3)</u>	22,872,383	I	See note <u>(4)</u>
Common Stock	09/23/2015		P		3,211 <u>(1) (2)</u>	A	\$ 524.4477 <u>(1) (5)</u>	22,875,594	I	See note <u>(4)</u>
Common Stock	09/23/2015		P		1,200 <u>(1) (2)</u>	A	\$ 525.8842 <u>(1) (6)</u>	22,876,794	I	See note <u>(4)</u>
	09/23/2015		P			A		22,880,266	I	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock			3,472 <u>(1) (2)</u>		\$ 526.9029 <u>(1) (7)</u>				See note <u>(4)</u>
Common Stock	09/23/2015	P	2,573 <u>(1) (2)</u>	A	\$ 527.8528 <u>(1) (8)</u>	22,882,839	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	4,694 <u>(1) (2)</u>	A	\$ 529.041 <u>(1) (9)</u>	22,887,533	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	8,689 <u>(1) (2)</u>	A	\$ 530.0952 <u>(1) (10)</u>	22,896,222	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	6,043 <u>(1) (2)</u>	A	\$ 530.6769 <u>(1) (11)</u>	22,902,265	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	2,544 <u>(1) (2)</u>	A	\$ 531.9284 <u>(1) (12)</u>	22,904,809	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	5,945 <u>(1) (2)</u>	A	\$ 533.233 <u>(1) (13)</u>	22,910,754	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	12,828 <u>(1) (2)</u>	A	\$ 534.4185 <u>(1) (14)</u>	22,923,582	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	19,042 <u>(1) (2)</u>	A	\$ 535.2162 <u>(1) (15)</u>	22,942,624	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	23,423 <u>(1) (2)</u>	A	\$ 536.2586 <u>(1) (16)</u>	22,966,047	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	20,730 <u>(1) (2)</u>	A	\$ 537.2133 <u>(1) (17)</u>	22,986,777	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	15,274 <u>(1) (2)</u>	A	\$ 538.3122 <u>(1) (18)</u>	23,002,051	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	11,212 <u>(1) (2)</u>	A	\$ 539.1918 <u>(1) (19)</u>	23,013,263	I		See note <u>(4)</u>
Common Stock	09/23/2015	P	3,729 <u>(1) (2)</u>	A	\$ 539.9825 <u>(1) (20)</u>	23,016,992	I		See note <u>(4)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not**

SEC 1474  
(9-02)

required to respond unless the form displays a currently valid OMB control number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sanofi 54, RUE LA BOETIE PARIS, IO 75008			X	

## Signatures

/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law 09/25/2015

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- (2) Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
- (3) Purchase prices range from \$523.04 to \$523.90 per share, inclusive.
- (4) Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,217,440 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

- (5) Purchase prices range from \$524.14 to \$525.09 per share, inclusive.
- (6) Purchase prices range from \$525.21 to \$526.17 per share, inclusive.
- (7) Purchase prices range from \$526.26 to \$527.22 per share, inclusive.
- (8) Purchase prices range from \$527.42 to \$528.33 per share, inclusive.
- (9) Purchase prices range from \$528.46 to \$529.44 per share, inclusive.
- (10) Purchase prices range from \$529.49 to \$530.46 per share, inclusive.
- (11) Purchase prices range from \$530.48 to \$531.18 per share, inclusive.
- (12) Purchase prices range from \$531.48 to \$532.46 per share, inclusive.
- (13) Purchase prices range from \$532.78 to \$533.77 per share, inclusive.
- (14) Purchase prices range from \$533.79 to \$534.75 per share, inclusive.
- (15) Purchase prices range from \$534.78 to \$535.77 per share, inclusive.
- (16) Purchase prices range from \$535.78 to \$536.75 per share, inclusive.
- (17) Purchase prices range from \$536.78 to \$537.75 per share, inclusive.
- (18) Purchase prices range from \$537.79 to \$538.78 per share, inclusive.
- (19) Purchase prices range from \$538.81 to \$539.79 per share, inclusive.
- (20) Purchase prices range from \$539.81 to \$540.00 per share, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.